Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xing Bai

Showing results (91-100 of 107) with videos related to

Pageof 11
Sort By:
Scientific Reports|May 13, 2024
Significance of atherosclerotic plaque location in recanalizing non-acute long-segment occlusion of the internal carotid arteryTong-Yuan Zhao, Gang-Qin Xu, Jiang-Yu Xue, et al.
International Journal of Oral Science|October 19, 2013
Reliability assessment and correlation analysis of evaluating orthodontic treatment outcome in Chinese patientsGuang-Ying Song, Zhi-He Zhao, Yin Ding, et al.
Journal of Interventional Medicine|November 22, 2021
Application of retrievable Solitaire AB stents in the endovascular treatment of acute ischemic strokeTeng-Fei Zhou, Liang-Fu Zhu, Tian-Xiao Li, et al.
Antibody Therapeutics|March 10, 2026
IMM2510, a novel anti-PD-L1/VEGF bispecific antibody for cancer immunotherapyDianze Chen, Zhuli Wu, Xiwen Zhao, et al.
Leukemia|December 27, 2022
IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα, exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRPα interaction and FcɣR engagement by simultaneously binding to CD47 and CD20 of B cellsJifeng Yu, Song Li, Dianze Chen, et al.
Journal of Hematology & Oncology|November 17, 2022
SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the "don't eat me" signal and activating the "eat me" signalJifeng Yu, Song Li, Dianze Chen, et al.
Molecules (Basel, Switzerland)|September 9, 2022
Crystal Structure of Human CD47 in Complex with Engineered SIRPα.D1(N80A)Jifeng Yu, Song Li, Dianze Chen, et al.
Frontiers in Oncology|October 18, 2023
The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signalingSong Li, Dianze Chen, Huiqin Guo, et al.
American Journal of Orthodontics and Dentofacial Orthopedics : Official Publication of the American Association of Orthodontists, Its Constituent Societies, and the American Board of Orthodontics|September 3, 2013
Validation of the American Board of Orthodontics Objective Grading System for assessing the treatment outcomes of Chinese patientsGuang-Ying Song, Sheldon Baumrind, Zhi-He Zhao, et al.
Antibody Therapeutics|October 17, 2023
IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapySong Li, Dianze Chen, Huiqin Guo, et al.
Pageof 11

Showing results (91-100 of 107) with videos related to

Sort By:
Pageof 11
Scientific Reports|May 13, 2024
Significance of atherosclerotic plaque location in recanalizing non-acute long-segment occlusion of the internal carotid arteryTong-Yuan Zhao, Gang-Qin Xu, Jiang-Yu Xue, et al.
International Journal of Oral Science|October 19, 2013
Reliability assessment and correlation analysis of evaluating orthodontic treatment outcome in Chinese patientsGuang-Ying Song, Zhi-He Zhao, Yin Ding, et al.
Journal of Interventional Medicine|November 22, 2021
Application of retrievable Solitaire AB stents in the endovascular treatment of acute ischemic strokeTeng-Fei Zhou, Liang-Fu Zhu, Tian-Xiao Li, et al.
Antibody Therapeutics|March 10, 2026
IMM2510, a novel anti-PD-L1/VEGF bispecific antibody for cancer immunotherapyDianze Chen, Zhuli Wu, Xiwen Zhao, et al.
Leukemia|December 27, 2022
IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα, exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRPα interaction and FcɣR engagement by simultaneously binding to CD47 and CD20 of B cellsJifeng Yu, Song Li, Dianze Chen, et al.
Journal of Hematology & Oncology|November 17, 2022
SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the "don't eat me" signal and activating the "eat me" signalJifeng Yu, Song Li, Dianze Chen, et al.
Molecules (Basel, Switzerland)|September 9, 2022
Crystal Structure of Human CD47 in Complex with Engineered SIRPα.D1(N80A)Jifeng Yu, Song Li, Dianze Chen, et al.
Frontiers in Oncology|October 18, 2023
The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signalingSong Li, Dianze Chen, Huiqin Guo, et al.
American Journal of Orthodontics and Dentofacial Orthopedics : Official Publication of the American Association of Orthodontists, Its Constituent Societies, and the American Board of Orthodontics|September 3, 2013
Validation of the American Board of Orthodontics Objective Grading System for assessing the treatment outcomes of Chinese patientsGuang-Ying Song, Sheldon Baumrind, Zhi-He Zhao, et al.
Antibody Therapeutics|October 17, 2023
IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapySong Li, Dianze Chen, Huiqin Guo, et al.
Pageof 11